XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 3,557 $ 3,745 $ 6,976 $ 7,285  
Selling, general and administrative 2,649 2,739 5,202 5,221  
Research and development 4,048 3,500 7,669 7,492  
Other current assets 37,065   37,065   $ 38,782
Accrued and other current liabilities 14,502   14,502   15,694
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 413 354 769 684  
Cost of sales 86 82 169 163  
Selling, general and administrative 40 43 72 82  
Research and development 16 18 28 38  
Other current assets 411   411   424
Accrued and other current liabilities 12   12   $ 713
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 370 317 682 609  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement $ 43 $ 37 $ 87 $ 75